 Irene Schauer
Concepts (312)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 16 | 2024 | 3906 | 1.020 |
Why?
| | Insulin Resistance | 13 | 2024 | 1243 | 0.950 |
Why?
| | Mitochondria, Muscle | 2 | 2024 | 121 | 0.880 |
Why?
| | Hyperinsulinism | 4 | 2022 | 113 | 0.870 |
Why?
| | Metabolic Syndrome | 4 | 2026 | 356 | 0.820 |
Why?
| | Hyperlipidemias | 3 | 2022 | 122 | 0.800 |
Why?
| | Luteinizing Hormone | 5 | 2026 | 190 | 0.780 |
Why?
| | Follicle Stimulating Hormone | 5 | 2026 | 249 | 0.740 |
Why?
| | Vascular Stiffness | 3 | 2024 | 487 | 0.700 |
Why?
| | Insulin | 10 | 2022 | 2507 | 0.590 |
Why?
| | Fatty Acids, Nonesterified | 3 | 2021 | 158 | 0.510 |
Why?
| | Diabetes Mellitus, Type 2 | 9 | 2024 | 2592 | 0.510 |
Why?
| | Muscle, Smooth, Vascular | 2 | 2010 | 452 | 0.500 |
Why?
| | Cross-Over Studies | 6 | 2024 | 610 | 0.480 |
Why?
| | Cyclic AMP Response Element-Binding Protein | 3 | 2014 | 145 | 0.390 |
Why?
| | Diabetic Angiopathies | 4 | 2017 | 263 | 0.320 |
Why?
| | Lipoproteins, LDL | 1 | 2010 | 119 | 0.300 |
Why?
| | Muscle, Skeletal | 7 | 2024 | 1800 | 0.280 |
Why?
| | Exercise | 6 | 2024 | 2206 | 0.270 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 266 | 0.270 |
Why?
| | Cardiovascular Diseases | 7 | 2024 | 2182 | 0.260 |
Why?
| | Fatty Acids | 1 | 2010 | 452 | 0.260 |
Why?
| | Bromocriptine | 2 | 2022 | 31 | 0.240 |
Why?
| | Atherosclerosis | 1 | 2010 | 409 | 0.230 |
Why?
| | Glucose Clamp Technique | 7 | 2021 | 199 | 0.230 |
Why?
| | Pulse Wave Analysis | 2 | 2023 | 266 | 0.220 |
Why?
| | Adult | 27 | 2026 | 40627 | 0.220 |
Why?
| | Lipids | 5 | 2022 | 712 | 0.220 |
Why?
| | Hypertension | 4 | 2010 | 1266 | 0.220 |
Why?
| | Young Adult | 10 | 2026 | 14163 | 0.210 |
Why?
| | Diet, High-Fat | 1 | 2026 | 262 | 0.210 |
Why?
| | Blood Glucose | 7 | 2024 | 2333 | 0.200 |
Why?
| | Adipose Tissue, Brown | 1 | 2024 | 60 | 0.200 |
Why?
| | Mitochondrial Diseases | 1 | 2024 | 93 | 0.200 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2024 | 162 | 0.190 |
Why?
| | Cardiorespiratory Fitness | 2 | 2024 | 74 | 0.190 |
Why?
| | Female | 30 | 2026 | 78605 | 0.190 |
Why?
| | Glucose Intolerance | 1 | 2024 | 142 | 0.180 |
Why?
| | Case-Control Studies | 4 | 2024 | 3613 | 0.180 |
Why?
| | Glycolysis | 1 | 2024 | 340 | 0.180 |
Why?
| | Oxygen | 2 | 2018 | 995 | 0.180 |
Why?
| | Human Growth Hormone | 1 | 2022 | 46 | 0.180 |
Why?
| | Signal Transduction | 2 | 2021 | 5239 | 0.180 |
Why?
| | Humans | 42 | 2026 | 145305 | 0.170 |
Why?
| | Leg | 2 | 2021 | 239 | 0.170 |
Why?
| | Magnetic Resonance Spectroscopy | 1 | 2024 | 631 | 0.170 |
Why?
| | Soybean Oil | 1 | 2021 | 15 | 0.170 |
Why?
| | Resistance Training | 1 | 2024 | 185 | 0.170 |
Why?
| | Adolescent | 14 | 2024 | 22507 | 0.170 |
Why?
| | Cyclins | 3 | 1997 | 84 | 0.160 |
Why?
| | Middle Aged | 19 | 2024 | 36021 | 0.160 |
Why?
| | Incretins | 1 | 2020 | 21 | 0.160 |
Why?
| | Oxidative Phosphorylation | 2 | 2019 | 210 | 0.160 |
Why?
| | Bone Remodeling | 1 | 2020 | 71 | 0.160 |
Why?
| | Bone Resorption | 1 | 2020 | 80 | 0.150 |
Why?
| | Obesity | 4 | 2023 | 3085 | 0.150 |
Why?
| | Dietary Fats | 3 | 2012 | 315 | 0.150 |
Why?
| | Male | 27 | 2024 | 72628 | 0.150 |
Why?
| | Exercise Tolerance | 2 | 2024 | 283 | 0.150 |
Why?
| | Phospholipids | 1 | 2021 | 214 | 0.150 |
Why?
| | Sitagliptin Phosphate | 1 | 2019 | 31 | 0.150 |
Why?
| | Retinoblastoma Protein | 2 | 2001 | 61 | 0.150 |
Why?
| | Glucose | 2 | 2024 | 1049 | 0.140 |
Why?
| | Diastole | 1 | 2019 | 143 | 0.140 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 46 | 0.140 |
Why?
| | Coronary Vessels | 2 | 2010 | 254 | 0.140 |
Why?
| | Osteogenesis | 1 | 2020 | 208 | 0.140 |
Why?
| | Cell Cycle Proteins | 3 | 1998 | 630 | 0.140 |
Why?
| | Hyperglycemia | 1 | 2022 | 376 | 0.140 |
Why?
| | Cancellous Bone | 1 | 2017 | 22 | 0.130 |
Why?
| | Lipoproteins | 3 | 2010 | 169 | 0.130 |
Why?
| | Body Fat Distribution | 1 | 2017 | 45 | 0.130 |
Why?
| | Tumor Suppressor Proteins | 2 | 1997 | 324 | 0.130 |
Why?
| | Pericardium | 1 | 2017 | 62 | 0.130 |
Why?
| | Subcutaneous Fat | 1 | 2017 | 78 | 0.120 |
Why?
| | Sleep | 1 | 2024 | 901 | 0.120 |
Why?
| | Aorta | 2 | 2010 | 431 | 0.120 |
Why?
| | Heart Failure | 1 | 2010 | 2331 | 0.120 |
Why?
| | Phosphorylation | 3 | 2010 | 1735 | 0.120 |
Why?
| | Adiponectin | 2 | 2022 | 244 | 0.120 |
Why?
| | Microvessels | 1 | 2017 | 99 | 0.120 |
Why?
| | Hyperlipoproteinemias | 2 | 1987 | 5 | 0.120 |
Why?
| | Cell Cycle | 2 | 1996 | 600 | 0.120 |
Why?
| | Blood Vessels | 1 | 2017 | 171 | 0.120 |
Why?
| | Oxygen Consumption | 4 | 2021 | 725 | 0.120 |
Why?
| | Cell Division | 4 | 2009 | 766 | 0.110 |
Why?
| | Calcium | 2 | 2010 | 1185 | 0.110 |
Why?
| | Absorptiometry, Photon | 2 | 2017 | 276 | 0.110 |
Why?
| | Glycerol | 3 | 2012 | 90 | 0.110 |
Why?
| | Coronary Artery Disease | 2 | 2011 | 743 | 0.100 |
Why?
| | Oncogene Proteins | 1 | 1994 | 61 | 0.100 |
Why?
| | Carcinoma, Small Cell | 1 | 1994 | 173 | 0.100 |
Why?
| | Body Composition | 2 | 2024 | 708 | 0.100 |
Why?
| | Double-Blind Method | 3 | 2024 | 2033 | 0.090 |
Why?
| | Cholesterol | 4 | 2010 | 408 | 0.090 |
Why?
| | Fatty Acids, Monounsaturated | 1 | 2012 | 54 | 0.090 |
Why?
| | Liver | 2 | 2012 | 1893 | 0.090 |
Why?
| | Estrogens | 2 | 2026 | 381 | 0.090 |
Why?
| | Cells, Cultured | 2 | 2010 | 4155 | 0.090 |
Why?
| | Lung Neoplasms | 2 | 1996 | 2652 | 0.090 |
Why?
| | Body Mass Index | 4 | 2026 | 2439 | 0.080 |
Why?
| | Caenorhabditis | 1 | 1990 | 3 | 0.080 |
Why?
| | Adipose Tissue | 2 | 2018 | 653 | 0.080 |
Why?
| | Adipocytes | 1 | 2012 | 223 | 0.080 |
Why?
| | Gonadotropin-Releasing Hormone | 2 | 2024 | 212 | 0.080 |
Why?
| | Triglycerides | 8 | 2012 | 521 | 0.080 |
Why?
| | Professional-Patient Relations | 1 | 2012 | 154 | 0.080 |
Why?
| | Creatinine | 2 | 2022 | 510 | 0.080 |
Why?
| | Rats, Inbred SHR | 1 | 2010 | 37 | 0.080 |
Why?
| | Cohort Studies | 4 | 2018 | 5982 | 0.080 |
Why?
| | Embryo, Nonmammalian | 1 | 1990 | 173 | 0.080 |
Why?
| | Receptors, LDL | 1 | 2010 | 53 | 0.080 |
Why?
| | Free Radical Scavengers | 1 | 2010 | 82 | 0.080 |
Why?
| | Abdomen | 1 | 2010 | 141 | 0.080 |
Why?
| | JNK Mitogen-Activated Protein Kinases | 1 | 2010 | 153 | 0.080 |
Why?
| | Age Factors | 4 | 2012 | 3339 | 0.070 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2010 | 173 | 0.070 |
Why?
| | Reference Values | 1 | 2010 | 798 | 0.070 |
Why?
| | Calcinosis | 1 | 2011 | 234 | 0.070 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2010 | 266 | 0.070 |
Why?
| | Spleen | 1 | 2010 | 508 | 0.070 |
Why?
| | Counseling | 1 | 2012 | 409 | 0.070 |
Why?
| | Enzyme Activation | 1 | 2010 | 768 | 0.070 |
Why?
| | Cyclin D1 | 2 | 2001 | 62 | 0.070 |
Why?
| | Propranolol | 3 | 1987 | 44 | 0.070 |
Why?
| | Environmental Monitoring | 1 | 2010 | 379 | 0.070 |
Why?
| | Phosphatidylcholine-Sterol O-Acyltransferase | 3 | 1985 | 8 | 0.070 |
Why?
| | Sex Characteristics | 3 | 2022 | 791 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2010 | 437 | 0.070 |
Why?
| | Down-Regulation | 1 | 2010 | 627 | 0.070 |
Why?
| | Mitochondria | 1 | 2014 | 987 | 0.060 |
Why?
| | Reactive Oxygen Species | 1 | 2010 | 622 | 0.060 |
Why?
| | Cell Nucleus | 1 | 2010 | 620 | 0.060 |
Why?
| | Pregnanediol | 1 | 2026 | 22 | 0.060 |
Why?
| | Cattle | 1 | 2009 | 1001 | 0.060 |
Why?
| | Estrone | 1 | 2026 | 40 | 0.060 |
Why?
| | Energy Metabolism | 2 | 2024 | 946 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 1 | 1987 | 250 | 0.060 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 1994 | 1183 | 0.060 |
Why?
| | Diabetes Mellitus | 1 | 2014 | 1098 | 0.060 |
Why?
| | Menstrual Cycle | 1 | 2026 | 140 | 0.060 |
Why?
| | Heparin | 2 | 2022 | 244 | 0.050 |
Why?
| | Rats, Sprague-Dawley | 1 | 2010 | 2541 | 0.050 |
Why?
| | Transcription, Genetic | 1 | 1990 | 1496 | 0.050 |
Why?
| | Thermogenesis | 1 | 2024 | 45 | 0.050 |
Why?
| | Sex Factors | 4 | 2018 | 2115 | 0.050 |
Why?
| | Arteriosclerosis | 1 | 1983 | 84 | 0.050 |
Why?
| | Protein Kinase Inhibitors | 1 | 2010 | 974 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2010 | 2745 | 0.050 |
Why?
| | Actigraphy | 1 | 2024 | 148 | 0.050 |
Why?
| | Intra-Abdominal Fat | 2 | 2017 | 100 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2010 | 3127 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2024 | 361 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 2022 | 15 | 0.050 |
Why?
| | Cold Temperature | 1 | 2024 | 210 | 0.050 |
Why?
| | Child | 6 | 2024 | 22712 | 0.050 |
Why?
| | Time Factors | 2 | 2010 | 7186 | 0.040 |
Why?
| | Positron-Emission Tomography | 1 | 2024 | 343 | 0.040 |
Why?
| | Prolactin | 1 | 2022 | 89 | 0.040 |
Why?
| | Growth Hormone | 1 | 2022 | 92 | 0.040 |
Why?
| | Thyroid Hormones | 1 | 2022 | 68 | 0.040 |
Why?
| | Thyrotropin | 1 | 2022 | 119 | 0.040 |
Why?
| | Cholesterol, HDL | 5 | 2011 | 200 | 0.040 |
Why?
| | Coronary Disease | 1 | 1983 | 386 | 0.040 |
Why?
| | Rats | 1 | 2010 | 5616 | 0.040 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2022 | 146 | 0.040 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 32 | 0.040 |
Why?
| | Muscle Strength | 1 | 2024 | 330 | 0.040 |
Why?
| | Emulsions | 1 | 2021 | 57 | 0.040 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2021 | 29 | 0.040 |
Why?
| | Primary Health Care | 1 | 2012 | 1737 | 0.040 |
Why?
| | Longevity | 1 | 2022 | 174 | 0.040 |
Why?
| | Aorta, Thoracic | 1 | 2023 | 286 | 0.040 |
Why?
| | Glucagon-Like Peptide 2 | 1 | 2020 | 7 | 0.040 |
Why?
| | Gastric Inhibitory Polypeptide | 1 | 2020 | 13 | 0.040 |
Why?
| | Thinness | 1 | 2021 | 99 | 0.040 |
Why?
| | Leptin | 1 | 2022 | 247 | 0.040 |
Why?
| | Genetic Fitness | 1 | 2021 | 59 | 0.040 |
Why?
| | Pituitary Gland | 1 | 2021 | 148 | 0.040 |
Why?
| | Heat-Shock Proteins | 1 | 2021 | 138 | 0.040 |
Why?
| | Risk Assessment | 1 | 2010 | 3686 | 0.040 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2021 | 120 | 0.040 |
Why?
| | Hydrocortisone | 1 | 2022 | 304 | 0.040 |
Why?
| | Insulin-Like Growth Factor I | 1 | 2022 | 319 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 188 | 0.040 |
Why?
| | Animals | 4 | 2010 | 38177 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 2 | 1997 | 73 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 2 | 1997 | 112 | 0.040 |
Why?
| | Disease Models, Animal | 1 | 2010 | 4580 | 0.040 |
Why?
| | Sulfonylurea Compounds | 1 | 2019 | 51 | 0.040 |
Why?
| | Placebos | 1 | 2019 | 193 | 0.040 |
Why?
| | Aging | 1 | 2010 | 1968 | 0.040 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 6007 | 0.040 |
Why?
| | Overweight | 1 | 2023 | 610 | 0.030 |
Why?
| | Cross-Sectional Studies | 3 | 2017 | 5883 | 0.030 |
Why?
| | Aged | 4 | 2022 | 26001 | 0.030 |
Why?
| | Cell Respiration | 1 | 2018 | 107 | 0.030 |
Why?
| | Fungal Proteins | 1 | 1998 | 145 | 0.030 |
Why?
| | Academic Medical Centers | 1 | 2021 | 548 | 0.030 |
Why?
| | CDC2-CDC28 Kinases | 1 | 1997 | 17 | 0.030 |
Why?
| | Research Design | 1 | 2024 | 1137 | 0.030 |
Why?
| | Capillary Resistance | 1 | 2017 | 4 | 0.030 |
Why?
| | Obesity, Abdominal | 1 | 2017 | 46 | 0.030 |
Why?
| | Tomography Scanners, X-Ray Computed | 1 | 2017 | 21 | 0.030 |
Why?
| | Oxyhemoglobins | 1 | 2017 | 28 | 0.030 |
Why?
| | Anthropometry | 1 | 2017 | 200 | 0.030 |
Why?
| | Random Allocation | 1 | 2018 | 363 | 0.030 |
Why?
| | Adiposity | 2 | 2012 | 545 | 0.030 |
Why?
| | Spectroscopy, Near-Infrared | 1 | 2017 | 70 | 0.030 |
Why?
| | Tumor Cells, Cultured | 2 | 1997 | 920 | 0.030 |
Why?
| | Microcirculation | 1 | 2017 | 145 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2022 | 699 | 0.030 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 1996 | 14 | 0.030 |
Why?
| | Molecular Weight | 2 | 2012 | 327 | 0.030 |
Why?
| | Microtubule-Associated Proteins | 1 | 1997 | 196 | 0.030 |
Why?
| | Hip Joint | 1 | 2017 | 172 | 0.030 |
Why?
| | Bicycling | 1 | 2017 | 120 | 0.030 |
Why?
| | Gene Expression | 1 | 2021 | 1490 | 0.030 |
Why?
| | Genes, Tumor Suppressor | 1 | 1996 | 83 | 0.030 |
Why?
| | Progesterone | 1 | 1997 | 256 | 0.030 |
Why?
| | Vascular Resistance | 1 | 2017 | 367 | 0.030 |
Why?
| | Lumbar Vertebrae | 1 | 2017 | 252 | 0.030 |
Why?
| | Waist Circumference | 1 | 2015 | 141 | 0.030 |
Why?
| | Regional Blood Flow | 1 | 2017 | 514 | 0.030 |
Why?
| | Osteoporosis | 1 | 2017 | 236 | 0.030 |
Why?
| | Hemoglobins | 1 | 2017 | 384 | 0.030 |
Why?
| | Saccharomyces cerevisiae Proteins | 1 | 1998 | 419 | 0.030 |
Why?
| | Mice | 2 | 2010 | 18394 | 0.030 |
Why?
| | Oxidative Stress | 1 | 2021 | 1341 | 0.030 |
Why?
| | Blood Pressure | 2 | 2017 | 1771 | 0.030 |
Why?
| | Bone Density | 1 | 2017 | 482 | 0.030 |
Why?
| | Saccharomyces cerevisiae | 1 | 1998 | 579 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 204 | 0.020 |
Why?
| | Exercise Therapy | 1 | 2018 | 474 | 0.020 |
Why?
| | Cytokines | 1 | 2021 | 2066 | 0.020 |
Why?
| | Risk | 2 | 1987 | 912 | 0.020 |
Why?
| | Risk Factors | 3 | 2012 | 10816 | 0.020 |
Why?
| | Protein Kinases | 1 | 1994 | 316 | 0.020 |
Why?
| | Abdominal Fat | 1 | 2012 | 50 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 682 | 0.020 |
Why?
| | Autoradiography | 1 | 1990 | 65 | 0.020 |
Why?
| | Electrophoresis | 1 | 1990 | 31 | 0.020 |
Why?
| | DNA Probes | 1 | 1990 | 59 | 0.020 |
Why?
| | Dietary Carbohydrates | 1 | 2012 | 151 | 0.020 |
Why?
| | Lipoproteins, HDL | 2 | 1981 | 101 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 2118 | 0.020 |
Why?
| | Health Expenditures | 1 | 2012 | 194 | 0.020 |
Why?
| | Nucleotides | 1 | 1990 | 129 | 0.020 |
Why?
| | Health Care Surveys | 1 | 2012 | 539 | 0.020 |
Why?
| | Adaptation, Physiological | 1 | 2014 | 572 | 0.020 |
Why?
| | Sex Distribution | 1 | 2010 | 386 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2019 | 1391 | 0.020 |
Why?
| | Pregnancy | 1 | 2022 | 7208 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 529 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 1997 | 2609 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2010 | 454 | 0.020 |
Why?
| | Lung | 1 | 2001 | 4112 | 0.020 |
Why?
| | Transcription Factors | 1 | 1996 | 1746 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1846 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 5431 | 0.020 |
Why?
| | Atenolol | 1 | 1987 | 7 | 0.020 |
Why?
| | Metoprolol | 1 | 1987 | 26 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2012 | 589 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1327 | 0.020 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 439 | 0.010 |
Why?
| | Patient Selection | 1 | 2010 | 726 | 0.010 |
Why?
| | Breast Neoplasms | 1 | 1997 | 2464 | 0.010 |
Why?
| | Diet | 1 | 2012 | 1285 | 0.010 |
Why?
| | Diet, Sodium-Restricted | 1 | 1983 | 38 | 0.010 |
Why?
| | Prospective Studies | 1 | 2015 | 8011 | 0.010 |
Why?
| | Smoking Prevention | 1 | 1983 | 166 | 0.010 |
Why?
| | Physical Exertion | 1 | 1983 | 207 | 0.010 |
Why?
| | Autoanalysis | 1 | 1981 | 8 | 0.010 |
Why?
| | Combined Modality Therapy | 1 | 1983 | 1268 | 0.010 |
Why?
| | Lipoprotein Lipase | 1 | 1980 | 56 | 0.010 |
Why?
| | Contraceptives, Oral, Hormonal | 1 | 1979 | 30 | 0.010 |
Why?
| | Contraceptives, Oral | 1 | 1979 | 37 | 0.010 |
Why?
| | Hybrid Cells | 1 | 1998 | 49 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2012 | 6079 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 1998 | 66 | 0.010 |
Why?
| | Precipitin Tests | 1 | 1998 | 93 | 0.010 |
Why?
| | Mice, Inbred BALB C | 1 | 2001 | 1253 | 0.010 |
Why?
| | Cyclin B | 1 | 1997 | 16 | 0.010 |
Why?
| | Promegestone | 1 | 1997 | 33 | 0.010 |
Why?
| | Cyclin A | 1 | 1997 | 18 | 0.010 |
Why?
| | Gonanes | 1 | 1997 | 28 | 0.010 |
Why?
| | Mifepristone | 1 | 1997 | 64 | 0.010 |
Why?
| | Hormone Antagonists | 1 | 1997 | 34 | 0.010 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p27 | 1 | 1997 | 66 | 0.010 |
Why?
| | G1 Phase | 1 | 1997 | 66 | 0.010 |
Why?
| | Cyclin-Dependent Kinase 2 | 1 | 1997 | 36 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 1997 | 172 | 0.010 |
Why?
| | Drug Synergism | 1 | 1997 | 357 | 0.010 |
Why?
| | Cyclin-Dependent Kinases | 1 | 1997 | 123 | 0.010 |
Why?
| | Myocardial Infarction | 1 | 1983 | 1211 | 0.010 |
Why?
| | Cell Line | 1 | 2001 | 2882 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2001 | 1126 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 1998 | 2158 | 0.010 |
Why?
| | ErbB Receptors | 1 | 1997 | 630 | 0.010 |
Why?
| | United States | 1 | 2012 | 16051 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1998 | 2931 | 0.010 |
Why?
| | Biomarkers | 1 | 2001 | 4284 | 0.000 |
Why?
| | Mutation | 1 | 1998 | 4104 | 0.000 |
Why?
| | Cholesterol Esters | 1 | 1985 | 7 | 0.000 |
Why?
| | Lipoproteins, VLDL | 1 | 1984 | 21 | 0.000 |
Why?
| | Injections, Intravenous | 1 | 1984 | 200 | 0.000 |
Why?
| | Microchemistry | 1 | 1981 | 19 | 0.000 |
Why?
| | Regression Analysis | 1 | 1984 | 1003 | 0.000 |
Why?
| | Capillaries | 1 | 1981 | 125 | 0.000 |
Why?
| | Germany, East | 1 | 1979 | 1 | 0.000 |
Why?
| | Occupational Medicine | 1 | 1979 | 14 | 0.000 |
Why?
| | Child, Preschool | 1 | 1981 | 11863 | 0.000 |
Why?
|
|
Schauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|